References
- van Meerbeeck JP, Damhuis R. Facts, rumours and speculations about the mesothelioma epidemic. Respirology. 2011;16:1018–1019.
- Roe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24:115–131.
- Porpodis K, Zarogoulidis P, Boutsikou E, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5:S397–S406.
- Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408.
- Patel SC, Dowell JE. Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl). 2016;7:63–72.
- Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841–1848.
- Robinson BWS, Lake RA. Medical progress: advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603.
- McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996;9:1932–1942.
- Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–672.
- Zhang W, Wu X, Wu L, et al. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med. 2015;3:182.
- Mott FE. Mesothelioma: a review. Ochsner J. 2012;12:70–79.
- Sauli N. President of the Rebuplic, Laura Räty, Minister of Social Affairs and Health. Työtapaturma- ja ammattitautilaki; [cited April 24, 2018]. Available from: http://www.finlex.fi/fi/laki/alkup/2015/20150459
- Ilkka K. Minister of Labour, Matti Kajantie SI. Valtioneuvoston päätös asbestin ja asbestipitoisen tuotteen valmistuksen, maahantuonnin, myymisen ja käyttöön ottamisen kieltämisestä; [cited April 24, 2018]. Available from: http://www.finlex.fi/fi/laki/alkup/1992/19920852
- Ilkka K. Minister of Labour, Matti Kajantie SI. Valtioneuvoston päätös asbestin ja asbestipitoisen tuotteen valmistuksen, maahantuonnin, myymisen ja käyttöön ottamisen kieltämisestä annetun valtioneuvoston päätöksen muuttamisesta; [cited April 24, 2018]. Available from: http://www.finlex.fi/fi/laki/alkup/1993/19931133
- Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based finnish cancer registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–39.
- Statistics Finland. Statistics finland's PX-web databases: population according to age (1-year) and sex by area 1972–2016; [cited April 24, 2018]. Available from: http://pxnet2.stat.fi/PXWeb/pxweb/en/StatFin/StatFin__vrm__vaerak/058_vaerak_tau_104.px/?rxid=146981e6-8fc8-40bc-bac8-a6320e704ff2
- Population Register Centre. Population information system; [cited April 24, 2018]. Available from: http://vrk.fi/en/population-information-system
- Finnish Medicines Agency (Fimea). Databases and registers, FimeaWeb, pemetrexed; [cited 2017]. Available from: http://www.fimea.fi/web/en/databases_and_registeries/fimeaweb
- Corfiati M, Scarselli A, Binazzi A, et al. Epidemiological patterns of asbestos exposure and spatial clusters of incident cases of malignant mesothelioma from the Italian National Registry. BMC Cancer. 2015;15:1–14.
- Montanaro F, Bray F, Gennaro V, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control. 2003;14:791–803.
- Neumann V, Loseke S, Nowak D, et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int. 2013;110:319–326.
- Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in Norway: a population-based study of 1686 cases. J Thorac Oncol. 2012;7:1858–1861.
- Jennings CJ, Walsh PM, Deady S, et al. Malignant pleural mesothelioma incidence and survival in the republic of Ireland 1994-2009. Cancer Epidemiol. 2014;38:35–41.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.
- Shukuya T, Takahashi T, Imai H, et al. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respir Investig. 2014;52:101–106.
- Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–965.
- Ak G, Metintas S, Metintas M, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol. 2009;4:1425–1430.